Extracorporeal blood purification treatment (EBT) methods have been used in the treatment of experimental and human SIRS/Sepsis in a variety of settings and with variable reports of efficacy and safety. Their role in the management of SIRS/Sepsis remains controversial.
Objectives
To develop consensus statements regarding important aspects of research, practice and technical management concerning EBT.
Methods
Systematic review of published study. Evidence-based grading of information available. Consensus development regarding fundamental questions about EBT.
Results
Consensus was achieved on all questions posed during the conference.
It was agreed that there is currently a clear biological rational for EBT in SIRS and Sepsis. It was agreed that conventional CVVH has sufficiently been shown not to be effective in SIRS/Sepsis in the absence of concomitant ARF and that other therapies such as plasmapheresis or high-volume hemofiltration or coupled plasma filtration adsorption appear more promising and should be tested in multicentre randomized controlled trials. Patients with ARF and SIRS/Sepsis should be treated differently from those with ARF alone even though current practice in this field is not well known. Patients with refractory septic shock should be considered for EBT. Appropriate end points for clinical trials can be defined and chosen according to the goals of the trial. Different technologies exist for EBT and better understanding of the merits and safety of each is needed as well as better standardization of methodology and dose.
Conclusions
Broad consensus can be achieved on several aspects of EBT and can be used to inform clinical practice and to help guide the establishment of a future research agenda.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference:Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.Crit Care Med1992; 20: 864–74.
2.
PinskyM., MatuschakG.. A unifying hypothesis of multiple systems organ failure: Failure of host defence homeostasis.J Crit Care1990; 5: 108–14.
3.
DamasP., CanivetJ.L., De GrooteD., VrindtsY., AlbertA., FranchimontP., LamyM.. Sepsis and serum cytokine concentrations.Crit Care Med1997; 25: 405–12.
4.
CaseyL., BalkR., BoneR.. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome.Ann Intern Med1993; 119: 771–8.
5.
PinskyM., VincentJ.L., AlegreM., DupontE.. Serum cytokine levels in human septic shock, Relation to multiple-system organ failure and mortality.Chest1993; 103: 565–75.
6.
DofferhoffA., BomV., de Vries-HospersH., van IngenJ., vd MeerJ., HazenbergB., MulderP., WeitsJ.. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans.Crit Care Med1992; 20: 185–92.
7.
HonoréP.M., ZydneyA.L., MatsonJ.R.. High volume and high permeability haemofiltration for sepsis: The evidence and the key issues.Care of the Critically ill2003; 19: 1–7.
8.
Garcia-FernandezN., LavillaF.J., RochaE., PurroyA.. Haemostatic changes in systemic inflammatory response syndrome during continuous renal replacement therapy.J Nephrol2000; 13: 282–9.
9.
YekebasE.F., StrateT., ZolmajdS., EisenbergerC.F., ErbesdablerA., SaalmullerA., SteffaniK., BurchC., ElsmerH.A., EngelhardtM., GillesenA., MeinsJ., theM., KnoeffelW.T., IzbickiJ.R.. Impact of different modalities of continuous venovenous hemofiltration on sepsis-induced alterations in experimental pancreatitis.Kidney Int2002; 62: 1806–18.
10.
BridgemanS., DointyK., KirkleyA., MaffuliN.. ISAKOS Scientific Committee. Practical Aspects of randomisation and blinding in randomized clinical trials.Arthroscopy2003; 19: 1000–6.
11.
BellomoR., AngusD., StarR.. The acute dialysis quality initiative - Part II: Patient selection for CRRT.Adv Ren Replace Ther2002; 9: 255–9.
12.
ReevesJ., ButtW., ShannF.. Continuous plasmafiltration in sepsis syndrome.Crit Care Med1999; 27: 2096–104.
13.
ColeL., BellomoR., HartG., JournoisD., DavenportP., TippingP., RoncoC.: A phase II randomized, controlled trial of continuous hemofiltration in sepsis.Crit Care Med2002; 30: 100–6.
14.
BusundR., KouklineV., UtrobinU., NedashkovskyE.. Plasmapheresis in severe sepsis and septic shock: A prospective, randomized, controlled trial.Intensive Care Med2002; 28: 1434–9.
15.
HonoréP.M., MatsonJ.R.. Hemofiltration, adsorption, sieving and the challenge of sepsis therapy design.Crit Care2002; 6: 394–6.
16.
RoncoC., BellomoR., HomelP., BrendolanA., DanM., PicciniP., La GrecaG.. Effects of different doses in continuous venovenous haemofiltration in outcomes of acute renal failure: A prospective randomized trial.Lancet2000; 355: 26–30.
17.
PhuN.H., HienT.T., MaiN.T.. Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam.N Engl J Med2002; 347: 895–902.
18.
BellomoR., FarmerM., WrightG., ParkinG., BoyceN.. Treatment of sepsis-associated severe acute renal failure with continuous hemodiafiltration: Clinical experience and comparison with conventional dialysis.Blood Purif1995; 13: 246–54.
19.
Oudemans-van StraatenH., BosmanR., van der SpoelJ., ZandstraD.. Outcome of critically ill patients treated with intermittent high-volume haemofiltration: A prospective cohort analysis.Intensive Care Med1999; 25: 814–21.
20.
PaganiniE., LariveB., KanagasundaramN.. Severity scores and outcomes with acute renal failure in the ICU setting.Contrib Nephrol2001; 132: 81–95.
21.
GotloibL., BarzilayE., ShustakA., ZviW., JaichenkoJ., LevA.. Hemofiltration in septic ARDS. The artificial kidney as an artificial endocrine lung.Resuscitation1986; 13: 123–32.
22.
MaritanoM., AvalleM., GianferrariP., GuglielmottiE., PacittiA., SegoloniG., VignottoF.. Changes in hemodynamics and alveolar-arterial oxygen tension difference in patients with adult respiratory distress syndrome during fluid removal by ultrafiltration. Continuous Arteriovenous Hemofiltration (CAVH).Int. Conf. On CAVH, Aachen1984; pp. 111–5(Karger, Basel 1985).
23.
CoraimF., FasolR., StellwagF., WolnerE.. Continuous arteriovenous hemofiltration (CAVH) after cardiac surgery. Continuous Arteriovenous Hemofiltration (CAVH). Int. Conf. On CAVH. Aachen 1984; pp. 116–24 (Karger, Basel 1985).
24.
HonoréP.M., JamezJ., WauthierM., LeeP., DugernierT., PirenneB., HaniqueG., MatsonJ.R.. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock.Crit Care Med2000; 28: 3581–7.
25.
HonoréP.M., MatsonJ.R.. Short-term high-volume hemofiltration in sepsis: Perhaps the right way is to start with.Crit Care Med2002; 30: 1673–4.
26.
BoumanC., Oudemans-van StraatenH., TijssenJ., ZandstraD., KeseciogluJ.. Effects of early high volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: A prospective, randomized trial.Crit Care Med2002; 30: 2205–11.
27.
LeeP.A., MatsonJ.R., PryorR.W., HinshawL.B.. Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine.Crit Care Med1993; 21: 914–24.
28.
YekebasE., EisenbergerC., OhnesorgeH.. Attenuation of sepsis-related immunoparalysis by continuous venovenous hemofiltration in experimental porcine pancreatitis.Crit Care Med2001; 29: 1423–30.
29.
DugernierT.L., LaterreP.F., WitteboleX., RoeselerJ., LatinneD., ReynaertM.S., PuginJ.. Compartmentalisation of the inflammatory response during acute pancreatitis: correlation with local and systemic complications.Am J Respir Crit Care Med2003; 168: 148–57.
30.
ColeL., BellomoR., JournoisD., DavenportP., BaldwinI., TippingP.. High-volume haemofiltration in human septic shock.Intensive Care Med2001; 27: 978–6.
31.
GotloibL., ShostakA., LevA., FudinR., JaichenkoJ.. Treatment of surgical and non-surgical septic multiorgan failure with bicarbonate hemodialysis and sequential hemofiltration.Intensive Care Med1995; 21: 104–11.
32.
RoncoC., BrendolanA., LonnemannG.. A pilot study of coupled plasma filtration with adsorption in septic shock.Crit Care Med2002; 30: 1250–5.
33.
BeatM., BeckerK., SchächingerH.. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit.Crit Care Med2000; 28: 977–83.
34.
HonoréP.M., JamezJ., WauthierM., PirenneB., PelgrimJ.P., DugernierTh. Removal of mediators by hemofiltration in septic shock: Where do we stand?Reanim Urgences2000; 9: 289–97.
35.
HonoréP.M., MatsonJ.R.. Extracorporeal removal for sepsis: Acting at the tissue level - The beginning of a new era for this treatment modality in septic shock.Crit Care Med2004; 32: 896–7.
36.
KloucheK., CavadoreP., PortalesP., ClotJ., CanaudB., BeraudJ.J.. Continuous veno-venous hemofiltration improves hemodynamics in septic shock with acute renal failure without modifying TNF-alpha and IL-6 plasma concentrations.J Nephrol2002; 15: 150–7.
37.
KellumJ.A., SongM., VenkataramanR.. Hemoadsorption removes TNF, IL-6 and IL-10, reduces NF kappa B DNA binding and improves short-term survival in lethal endotoxemia.Crit Care Med2004; 32: 801–5.
38.
HonoréP.M., JamezJ., WauthierM., DugernierT.. Propective evaluation of short-time high volume isovolemic hemofiltration on the haemodynamic course and outcome of patients with refractory septic shock.Crit Care Nephrol1998; 90: 87–99.
39.
SharmaV.K., DellingerR.P.. Recent developments in the treatment of sepsis.Expert Opin Investig Drugs2003; 12: 139–52.
40.
RogiersP., ZhangH., SmailN., PauwelsD., VincentJ.. Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-α attenuation during endotoxic shock.Crit Care Med1999; 27: 1848–55.
41.
KellumJ.A., JohnsonJ., KramerD., PalevskyP., BradyJ., PinskyM.. Diffusive vs. convective therapy: Effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome.Crit Care Med1998; 26: 1995–2000.
42.
LonnemannG., BechsteinM., LinnenweberS., BurgM., KockK.. Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure.Kidney Int1999; 56: (suppl 72) S84–7.
43.
UchinoS., BellomoR., GoldsmithC., DavenportP., ColeL., BaldwinI., PanagiotopoulosS., TippingP.. Super high flux hemofiltration: A new technique for cytokine removal.Intensive Care Med2002; 28: 651–5.
44.
LeeP.A., WegerG.W., PryorR.W., MatsonJ.R.. Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration (CAVH) therapy for Staphylococcus aureus-induced septicemia in immature swine.Crit Care Med1998; 26: 730–7.
45.
TettaC., GianottiL., CavaillonJ., WrattenM., FiniM, BragaM., BisagniP., GiavaresiG., BolzaniR., GiardinoR.. Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock.Crit Care Med2000; 28: 1526–33.
46.
PalmerJ., RifkindD.. Neutralization of the hemodynamic effects of endotoxin by polymyxin B.Surg Gynecol Obstet1974; 138: 755–9.
47.
TaniT., HanasawaK., EndoY.. Therapeutic apheresis for septic patients with organ dysfunction: Hemoperfusion using a polymyxin B immobilised column.Int J Artif Organs1998; 22: 1038–44.
48.
SuzukiH., NemotoH., NakamotoH.. Continuous hemodiafiltration with polymyxin-B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure.Ther Apher2002; 6: 234–40.
49.
UriuK., OsajimaA., HiroshigeK.. Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbances in patients with septic shock.Am J Kidney Dis2002; 39: 937–47.
50.
van BommelE.F.H.. Renal replacement therapy for acute renal failure on the intensive care unit: coming of age?Neth J Med2003; 61: 239–48.
51.
LeblancM., TapolyaiM., PaganiniE.P.. What dialysis dose should be provided in acute renal failure? A review.Adv Ren Replace Ther1995; 2: 255–64.
